Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lifted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 6.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 644,675 shares of the biotechnology company’s stock after purchasing an additional 37,940 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Sarepta Therapeutics were worth $101,858,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in SRPT. Principal Securities Inc. purchased a new position in Sarepta Therapeutics in the fourth quarter valued at $26,000. Mather Group LLC. acquired a new position in shares of Sarepta Therapeutics during the first quarter worth about $28,000. Riggs Asset Managment Co. Inc. grew its position in shares of Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares in the last quarter. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth approximately $31,000. Finally, New Covenant Trust Company N.A. purchased a new stake in shares of Sarepta Therapeutics during the first quarter worth approximately $32,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Up 0.1 %

SRPT stock opened at $127.21 on Friday. The company has a market cap of $12.02 billion, a price-to-earnings ratio of 1,156.45 and a beta of 0.81. The company has a fifty day moving average price of $137.26 and a 200 day moving average price of $132.66. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period last year, the firm earned ($0.27) EPS. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on SRPT. Piper Sandler lowered their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Evercore ISI raised shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and decreased their price objective for the stock from $185.00 to $179.00 in a research report on Thursday, August 8th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Sarepta Therapeutics in a report on Thursday. Barclays decreased their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $152.00 price objective on shares of Sarepta Therapeutics in a research report on Friday. Three analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.39.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now owns 21,261 shares in the company, valued at approximately $3,467,243.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now owns 21,261 shares in the company, valued at approximately $3,467,243.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ryan Edward Brown sold 38,957 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now directly owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The disclosure for this sale can be found here. Insiders have sold a total of 52,801 shares of company stock worth $8,399,586 in the last three months. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.